Preclinical studies indicate that CDK4/6 inhibition can increase tumor cell MHC class I expression and augment T-cell activation, while also reducing regulatory T-cell infiltration in certain models, thereby enhancing cytotoxic T-cell–mediated immunity (56–58). This evidence concerns the gene CDK4 and neoplasm.